Papers 10,000
1 page of 1,000 pages (10k results)
#1David Pereyra (Medical University of Vienna)H-Index: 10
#2Mattias Mandorfer (Medical University of Vienna)H-Index: 29
Last. Patrick Starlinger (Mayo Clinic)H-Index: 19
view all 4 authors...
We want to thank Luo MS and Huang GJ for their interest in our study. In their Letter to the Editor, they raise concerns about discrepancies in patient characteristics between included cohorts.
#1Marc G. Ghany (NIH: National Institutes of Health)H-Index: 71
#2Wendy C. King (University of Pittsburgh)H-Index: 39
Last. Richard K. Sterling (VCU: Virginia Commonwealth University)H-Index: 75
view all 12 authors...
We wish to respond to the comments received from Drs. Wu, Tseng and Kao. Our analysis was focused on comparing HBV RNA and hepatitis B core related antigen (HBcrAg) levels with existing markers of hepatitis B virus (HBV) replication (HBV DNA and hepatitis B surface antigen) and whether the two novel markers could improve distinguishing the different phases of infection.
#1Meng-Si Luo (GZUCM: Guangzhou University of Chinese Medicine)
#2Guan-Jiang Huang (ZJU: Zhejiang University)
With great interest, we read a study about a novel model modification for end-stage liver disease-sodium (MELD).(1) Starlinger P and colleagues concluded that the addition of C-reactive protein (CRP) and von Willebrand factor antigen (vWF-Ag) to the Model for End-Stage Liver Disease-Sodium (MELD-Na) improves the prediction of waitlist mortality. However, several crucial concerns attached our due attention.
#1Jer-Wei Wu (NTU: National Taiwan University)H-Index: 1
#2Tai-Chung Tseng (NTU: National Taiwan University)H-Index: 30
Last. Jia-Horng KaoH-Index: 93
view all 3 authors...
We read with great interest the article entitled "Comparison of Novel Biomarkers with Conventional HBV Markers among Untreated Adults with Chronic Hepatitis B in North America" by Ghany et al.1 Patients with chronic hepatitis B (CHB) are at risk of developing hepatocellular carcinoma (HCC) and serum markers reflecting viral replication could serve as HCC predictors. In addition to serum HBV DNA, hepatitis B core-related antigen (HBcrAg) and HBV RNA levels are two novel viral biomarkers correlate...
#1Panagiota Palla (National and Kapodistrian University of Athens)
Last. Theodoros Androutsakos (National and Kapodistrian University of Athens)H-Index: 4
view all 4 authors...
We are pleased to respond to Dr. Mungmunpuntipantip's observations on our recent paper (1). We totally agree that it is usually difficult to associate autoimmune hepatitis (AIH) like syndrome with a drug or vaccine administration. However, more and more cases of post-anti- severe acute respiratory syndrome coronavirus-2(SARS-CoV-2) vaccination are being recorded (2-5).
We would like to correspond on the issue of autoimmune hepatitis (AIH) following COVID-19 vaccination [1]. Palla et al .mentioned for AIH cases and discuss on the possible association between AIH and COVID-19 vaccination [1]. Vaccine adverse effect is possible and liver problem flowing vaccination is an interesting clinical problem. Some researchers propose that abnormal immune response is the definitive cause of AIH [2].
#1Alexander Laemmle (UB: University of Bern)H-Index: 2
#2Martin Poms (Boston Children's Hospital)H-Index: 4
Last. Holger Willenbring (UCSF: University of California, San Francisco)H-Index: 32
view all 10 authors...
Background & aims null Patient-derived human induced pluripotent stem cells (hiPSCs) differentiated into hepatocytes (hiPSC-Heps) have facilitated the study of rare genetic liver diseases. Here, we aimed to establish an in vitro liver disease model of the urea cycle disorder ornithine transcarbamylase deficiency (OTCD) using patient-derived hiPSC-Heps. null Approach & results null Before modeling OTCD, we addressed the question of why hiPSC-Heps generally secrete less urea than adult primary hum...
#1Sumeet K. Asrani (BUMC: Baylor University Medical Center)H-Index: 31
#2Marwan Ghabril (IU: Indiana University)H-Index: 30
Last. Elliot B. Tapper (UM: University of Michigan–Ann Arbor)H-Index: 37
view all 26 authors...
Background and aims null The burden of hepatocellular carcinoma (HCC) is substantial. To address gaps in HCC care, the American Association for the Study of Liver Diseases (AASLD) Practice Metrics Committee (PMC) aimed to develop a standard set of process-based measures and patient-reported outcomes along the HCC care continuum. null Approach and results null We identified candidate process and outcomes measures for HCC care based on structured literature review. A 13-member panel with content e...
#1Jennifer R. Kramer (BCM: Baylor College of Medicine)H-Index: 54
#2Yamini Natarajan (BCM: Baylor College of Medicine)H-Index: 9
Last. Fasiha Kanwal (BCM: Baylor College of Medicine)H-Index: 62
view all 7 authors...
BACKGROUND AND AIMS In patients with nonalcoholic fatty liver disease (NAFLD), those with type 2 diabetes (DM) have a high risk of progression to hepatocellular carcinoma (HCC). However, the determinants of HCC risk in these patients remain unclear. APPROACH AND RESULTS We assembled a retrospective cohort of patients with NAFLD and DM diagnosed at 130 facilities in the Veterans Administration between 1/1/2004 and 12/31/2008. We followed patients from the date of NAFLD diagnosis to HCC, death or ...
#1Yang Wang (Fudan University)H-Index: 6
#2Yumeng Li (Fudan University)
Last. Zhenghong Yuan (CAMS&PUMC: Chinese Academy of Medical Sciences & Peking Union Medical College)H-Index: 51
view all 10 authors...
Background and aims null Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is a major obstacle for a cure of chronic hepatitis B. Accumulating evidence suggests that epigenetic modifications regulate the transcriptional activity of cccDNA minichromosomes. However, it remains unclear how the epigenetic state of cccDNA affects its stability. null Approaches and results null By using HBV infection cell models, in vitro and in vivo recombinant cccDNA (rcccDNA) and the HBVcircle models,...
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.